Sign In

Neil Littman

Professional based in San Francisco, California

Neil Littman is the Chief Executive Officer (CEO) of ReIGNITE Therapeutics, Inc., a company focused on developing high-capacity viral vector technologies.1 He is an experienced executive in the biotechnology and healthcare investment sectors with a diverse background spanning multiple roles and companies.

Career Highlights

Bioverge Ventures:: Littman is the Founder and General Partner of Bioverge Ventures, a financial technology platform he established in 2016. The company aims to make healthcare venture capital more accessible to various investors, providing opportunities to invest in cutting-edge healthcare startups.1

Notable:: Prior to his current role, Littman served as the Vice President of Business Development at Notable from August 2018 to February 2020. Notable is a translational drug development platform focused on blood cancer therapeutics.1

California Institute for Regenerative Medicine (CIRM):: From November 2012 to July 2018, Littman held the position of Director of Business Development at CIRM, where he was involved in strategic collaborations and partnerships with biopharma companies and investors.1

Educational Background

Littman attended the University of Colorado, Boulder, where he earned his Bachelor's degree in Molecular, Cellular, and Developmental Biology. During his time there, he also gained experience working in a virology lab.2

Professional Philosophy

Littman's professional focus appears to be on bringing innovative healthcare technologies to life. He has expressed a commitment to developing groundbreaking therapies and making investments in healthcare startups that are "pushing the boundaries of healthcare to bring science fiction to life".13

Highlights

Aug 1 · linkedin

“Biotech is the ultimate impact investment.”

I read that quote from Robin Lauber in an article in the Financial Times about how family offices are increasingly turning to venture capital in healthcare and biotech. His analysis captures the essence of the transformative potential within biotechnology.

It comes as no surprise that family offices are increasingly drawn to venture capital in healthcare and biotech. This rapidly evolving sector not only presents opportunities for impressive financial returns, but it also offers a unique chance to address some of the most pressing challenges in longevity, disease therapeutics, and beyond.

Investing in biotech allows us to make a profound impact on the lives of individuals and communities. Through innovative research, breakthrough discoveries, and the development of cutting-edge therapies, we have the power to change the course of human health and well-being.

What do you think? Do you agree that biotech offers the best possible worlds between return and societal benefit?

#TechBio #VentureCapital #ImpactInvesting #Investment

Jul 27 · linkedin

Are you familiar with the history of personalized medicine?

Personalized medicine has a rich history, first dating back to the early 20th century. The “one-size-fits-all” view of medicine was first challenged with Karl Landsteiner's groundbreaking work on the ABO blood group system. Landsteiner’s research demonstrated blood transfusions could not be universal—one of the first ways in which we recognized biological differences inherent in each person.

The idea of genetic inheritance was pioneered by Sir Archbald Garrod, whose studies of alkaptonuria laid the basis for understanding inherited diseases of metabolism. And of course, we wouldn’t be able to understand precision medicine without the discoveries of DNA, beginning with Friedrich Miescher's discovery in 1869, and subsequent investigations by Phoebus Levene, Erwin Chargaff, James Watson, Rosalind Franklin, and Francis Crick.

But it was really the Human Genome Project that facilitated the evolution towards personalized medicine.

The Human Genome Project (HGP) was an international scientific effort that aimed to map and sequence the entire human genome, which is the complete set of genetic information in our DNA. Launched in 1990 and completed to 92% in 2003 (the genome was only completely sequenced in 2022), the project involved scientists from around the world.

The HGP not only provided a comprehensive reference for the human genome but also paved the way for subsequent research in genomics and personalized medicine.

This precision approach to personalized medicine is nothing short of a monumental change in healthcare. Bioverge Ventures's investment philosophy has been grounded in developing and nurturing companies charting these groundbreaking biotechnologies. We believe that only together can we unlock new frontiers in medicine, bringing hope and improved outcomes to millions of patients worldwide.

#TechBio #PersonalizedMedicine #History #ScienceHistory

Related Questions

What are Neil Littman's key achievements at ReIGNITE Therapeutics, Inc?
How did Neil Littman transition from investment banking to biotech leadership?
What is the mission of Bioverge Ventures under Neil Littman's leadership?
Can you provide more details about Neil Littman's role at the California Institute for Regenerative Medicine?
What are some notable projects Neil Littman has worked on at Notable?
Neil Littman
Neil Littman, photo 1
Neil Littman, photo 2
Add to my network

Experience

Bioverge Ventures

Education

The Johns Hopkins University

Location

San Francisco, California, United States